Get the Daily Brief
Latest Biotech News
Biopharma M&A – UCB expands epilepsy with Neurona buy
UCB agreed to acquire Neurona Therapeutics for up to $1.2 billion, positioning the Belgian drugmaker to move beyond its small-molecule core into seizure cell therapy. The deal adds an...
Oncology platforms – dual-payload antibody drug conjugates edge toward clinic
AACR spotlighted dual-payload antibody-drug conjugates as a next-generation modality as the field pushes into clinical translation. The Biocentury product development coverage cited more than 40...
Infectious disease surveillance – wastewater flags drug-resistant Candida auris
Researchers reported that wastewater-based epidemiology can detect the emergence of clinically significant, drug-resistant Candida auris strains in healthcare settings. A study by Chang, Moshi,...
Genetic medicine – base editing corrects cardiac Fabry mutation in cells
A Gene Therapy paper described adenine base editing (ABE) that corrects a cryptic splice mutation linked to cardiac-type Fabry disease in cells. Researchers targeted the IVS4+919 G>A mutation...
Cell therapy in transplantation – regulatory dendritic cells enable early immunosuppression withdrawal
Researchers reported results from a clinical trial testing regulatory dendritic cells (DCreg) to manage immune response after living-donor liver transplantation. The approach combines DCreg...
Company launch – 10x Genomics Atera spatial whole-transcriptome platform
10x Genomics unveiled Atera, a new spatial platform positioned to deliver whole-transcriptome spatial biology at scale. The company presented the instrument at AACR, describing a design meant to...
Biotech funding/IPO – Alamar goes public with $220M IPO
Alamar Biosciences priced its IPO at $17 per share, selling 12,937,500 shares and raising about $220 million in gross proceeds. Shares jumped in early trading after beginning to trade on Nasdaq...
Biotech IPO – Kailera upsizes to fund obesity pipeline in Phase 3
Kailera Therapeutics priced an upsized US IPO to raise $625 million, with the proceeds earmarked for clinical development of its obesity drug candidates. Coverage notes the company’s obesity-first...
Pancreatic cancer—KRAS targeting delivers a survival step
Revolution Medicines reported survival results from its Phase 3 pancreatic adenocarcinoma study of daraxonrasib, a daily oral KRAS inhibitor. In the trial, patients lived a median of 13.2 months...
FDA policy environment—enforcement and agency priorities
FDA’s Office of Prescription Drug Promotion (OPDP) is stepping up enforcement activity, focusing scrutiny on advertising tone, imagery, and whether promotional claims match clinical evidence. The...
FDA/Regulatory outlook—pediatric priority review voucher policy
FDA’s budget proposal includes a set of policy priorities, including a move to make pediatric priority review vouchers permanent. The budget plan also signals continued pressure on agency advisory...
Global genomics infrastructure—Poland scales national sequencing
The Polish Population Genomics Project secured PLN 248 million to sequence up to 7,000 individuals and build a national infrastructure for genomic research. Funders include support routed through...
Company IPOs—Kailera raises record funding for obesity pipeline
Kailera Therapeutics priced an upsized IPO to raise $625 million, targeting a late-stage obesity pipeline led by ribupatide (KAI-9531), a once-weekly GLP-1/GIP dual agonist peptide. The offering...
Acquisitions—UCB pays up for Neurona to add seizure cell therapy
UCB agreed to acquire Neurona for up to $1.2 billion, aiming to broaden beyond its small-molecule epilepsy base. The deal is designed to diversify its seizure treatment portfolio with a...
Gene therapy development—Roche targets EMA approval path for Elevidys
Roche outlined a route to EMA approval for its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec) by announcing a further global Phase 3 trial. The study is intended...
Precision diagnostics—Alamar Biosciences launches clinical proteomics instrument route to FDA clearance
Alamar Biosciences began trading on Nasdaq after pricing a $220 million IPO, signaling continued demand for proteomics platforms that can move toward regulated diagnostics. The company plans to...
Regulatory/biotech workforce—biopharma layoffs slow but not uniformly
Biopharma layoffs and projected cuts moderated year over year in Q1 2026, but total affected employees rose. Reporting from BioSpace indicates 35 companies made or planned cuts in Q1 2026 versus...
Next-gen diagnostics—10x Genomics unveils Atera spatial platform
10x Genomics launched Atera, a whole-transcriptome spatial biology instrument designed to close gaps in throughput and measurement trade-offs compared with existing spatial tools. The company...
Pancreatic cancer KRAS breakthrough nears approval
Revolution Medicines’ daraxonrasib posted a major survival benefit in a Phase 3 pancreatic cancer trial, strengthening the case for a new class of KRAS-targeted therapies in a disease that...
Pan-RAS oncology readout sparks M&A speculation
A separate report on Revolution Medicines’ KRAS/pan-RAS momentum highlights how the latest clinical outcome has shifted market perceptions around potential corporate actions. The story frames the...